Provide feedbackProvide feedback
Home :: Neurology

NIH, Banner Alzheimer's Institute, Genentech collaborate to evaluate crenezumab in prevention of AD

Wednesday, May 16 2012 | Comments
Evidence Grade 0 What's This?

The National Institutes of Health, the Banner Alzheimer's Institute, Genentech Inc. and the University of Antioquia in Colombia are collaborating on the first trial to evaluate a drug in the prevention of Alzheimer's disease (AD) among cognitively healthy individuals with a genetic risk of developing AD. The $100 million trial is the cornerstone of the Alzheimer's Prevention Initiative, a new international collaborative effort to accelerate the evaluation of promising but unproven...

The National Institutes of Health, the Banner Alzheimer's Institute, Genentech Inc. and the University of Antioquia in Colombia are collaborating on the first trial to evaluate a drug in the prevention of Alzheimer's disease (AD) among cognitively healthy individuals with a genetic risk of developing AD.

The $100 million trial is the cornerstone of the Alzheimer's Prevention Initiative, a new international collaborative effort to accelerate the evaluation of promising but unproven therapies for the prevention of AD.

The double-blind trial will evaluate crenezumab, an investigational anti-amyloid antibody, in approximately 300 people from a large extended family in Colombia who share a rare genetic mutation that typically triggers AD symptom onset at approximately age 45 years. The drug will also be evaluated in a smaller number of individuals in the United States. All participants will be aged 30 years or older with normal cognitive function at enrollment.

To avoid revealing the genetic status of the participants, most of whom do not want to know if they have the genetic mutation that increases their AD risk, the study will also include relatives who are noncarriers who will receive placebo.

The participants will receive injections of crenezumab or placebo at fixed intervals for up to five years. Researchers will use imaging techniques, cerebrospinal fluid tests and cognitive measures to monitor whether accumulation of amyloid and certain other proteins in the brain is reduced, whether brain size and function is maintained and whether mental performance is preserved.

The study will test the "amyloid hypothesis," which suggests that accumulation of the amyloid protein in the brain plays a key role in the progression of AD. Preclinical data indicate that crenezumab works by binding amyloid proteins and clearing them from the brain.

Genentech will contribute the majority of the funding for the trial, in addition to providing the study drug, as well as clinical and operational expertise.

Crenezumab is also currently being evaluated in a Phase II trial of patients with mild to moderate AD symptoms. The drug was selected for use in the prevention trial with guidance from an expert advisory panel.

Genentech is developing crenezumab in collaboration with Swiss biotech company AC Immune SA.

Latest News

Newron reports positive Phase III data for safinamide as treatment for PD; regulatory filings planned for 2013 Verusmed

Wednesday, May 16 2012 | Comments
Evidence Grade 0 What's This?

Newron Pharmaceuticals SpA's safinamide demonstrated efficacy as an add-on therapy for patients with Parkinson's disease (PD) in the final two Phase III trials of the drug's development program.

With these positive findings, the firm said it expects filings for regulatory approvals of the drug to begin in markets worldwide next year.

The MOTION and SETTLE trials were both six-month, double-blind, placebo-controlled...



FDA unclear on link between Novartis' MS drug Gilenya, patient deaths Verusmed

Monday, May 14 2012 | Comments
Evidence Grade 0 What's This?

The Food and Drug Administration said it could not definitively conclude that Novartis Pharmaceutical Corp.'s multiple sclerosis (MS) treatment Gilenya (fingolimod) was connected with the deaths of any patients who took the drug.

The agency issued a statement after completing its review of a report of a patient who died last December within 24 hours after taking the first dose...

Tags: Multiple Sclerosis


Biogen Idec's NDA for investigational MS therapy accepted for FDA review Verusmed

Thursday, May 10 2012 | Comments
Evidence Grade 0 What's This?

The Food and Drug Administration accepted for review Biogen Idec Inc.'s New Drug Application for BG-12 (dimethyl fumarate), an oral therapeutic candidate for the treatment of patients with multiple sclerosis (MS).

The NDA, which Biogen Idec submitted in late February, was supported by a clinical development program in which BG-12 provided significant...



Lundbeck, Takeda report positive Phase III data for investigational antidepressant Verusmed

Wednesday, May 09 2012 | Comments
Evidence Grade 0 What's This?

H. Lundbeck A/S and Takeda Pharmaceutical Co. Ltd.'s Lu AA21004, an investigational antidepressant, met the primary endpoint of a Phase III trial in which the compound was being evaluated as a treatment for major depressive disorder (MDD)...





Neurology Conference Coverage
  1. No articles have been read
  1. No articles have been emailed
Videos